Xelaglifam, a novel GPR40/FFAR1 agonist, exhibits enhanced β-arrestin recruitment and sustained glycemic control for type 2 diabetes
-
Published:2024-08
Issue:
Volume:177
Page:117044
-
ISSN:0753-3322
-
Container-title:Biomedicine & Pharmacotherapy
-
language:en
-
Short-container-title:Biomedicine & Pharmacotherapy
Author:
Yoon JongminORCID,
Lee Don-Gil,
Song Haengjin,
Hong Dahae,
Park Ji Soo,
Hong ChangheeORCID,
An Kyung Mi,
Lee Jung Woo,
Park Joon-TaeORCID,
Yoon Hongchul,
Tak Jihoon,
Kim Sang GeonORCID